A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2015 Results published in the British Journal of Cancer.
- 31 Aug 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.